# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
William Blair analyst Matt Larew downgrades Amedisys (NASDAQ:AMED) from Outperform to Market Perform.
Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.
Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $1.02 by 0.9...
Raymond James analyst John Ransom maintains Amedisys (NASDAQ:AMED) from Market Perform to Market Perform.
RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $97 to $...
Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.940 per share which missed the analyst consensus estimate of $1.030 by...
Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.03 by 8...
Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering adva...
Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.08 by 9...